BC Week In Review | Jun 16, 2014
Clinical News

Entereg alvimopan regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Week In Review | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Week In Review | Oct 28, 2013
Clinical News

Entereg alvimopan regulatory update

Cubist said FDA approved an sNDA for Entereg alvimopan to accelerate upper and lower GI recovery following any surgery that includes a partial bowel resection with primary anastomosis. The mu opioid receptor ( OPRM1 ; MOR)...
BC Week In Review | Jul 22, 2013
Clinical News

Bevenopran: Phase III started

Cubist began 3 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 0.25 mg oral bevenopran twice daily for 12 weeks each in about 600 patients receiving opioid therapy for chronic non-cancer pain. The trials...
BioCentury | Jan 28, 2013
Finance

Oleg's asymmetry

Longtime BVF Partners portfolio manager Oleg Nodelman is betting there's room for a new fund focused on what he calls "asymmetric opportunities." Last October, Nodelman left the hedge fund after about 11 years to launch...
BC Week In Review | Jan 7, 2013
Clinical News

Entereg alvimopan regulatory update

On Dec. 21, 2012, Cubist said it submitted an sNDA to FDA for Entereg alvimopan to accelerate GI recovery following any surgery that includes a bowel resection with primary anastomosis. The mu opioid receptor ( OPRM1...
BC Week In Review | Nov 5, 2012
Clinical News

CB-5945: Phase III started

Cubist began a double-blind, placebo-controlled, North American Phase III trial to evaluate 0.25 mg oral CB-5945 twice daily for 1 year in about 1,400 patients receiving opioid therapy for chronic non-cancer pain. The long-term safety...
BioCentury | Oct 22, 2012
Finance

Abbott's wild ride

Abbott Laboratories (NYSE:ABT) had a rollercoaster ride last week, gaining $4.3 billion in market cap on positive HCV data before losing more than $8.6 billion on details of its AbbVie pharmaceutical spinout and safety signals...
BC Extra | Sep 5, 2012
Company News

Kalidex debuts

Kalidex Pharmaceuticals Inc. (Menlo Park, Calif.) made its public debut on Tuesday and said it raised $45 million in a series A round in February 2011. Frazier Healthcare Ventures; Domain Associates; Canaan Partners; New Leaf...
BioCentury | Jul 23, 2012
Finance

In like a lion . . .

Human Genome Sciences Inc. (NASDAQ:HGSI) roared into biotech in the early 1990s with its genomics database. But it's going out like a lamb after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to acquire the biotech last week...
Items per page:
1 - 10 of 432
BC Week In Review | Jun 16, 2014
Clinical News

Entereg alvimopan regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Week In Review | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Week In Review | Oct 28, 2013
Clinical News

Entereg alvimopan regulatory update

Cubist said FDA approved an sNDA for Entereg alvimopan to accelerate upper and lower GI recovery following any surgery that includes a partial bowel resection with primary anastomosis. The mu opioid receptor ( OPRM1 ; MOR)...
BC Week In Review | Jul 22, 2013
Clinical News

Bevenopran: Phase III started

Cubist began 3 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 0.25 mg oral bevenopran twice daily for 12 weeks each in about 600 patients receiving opioid therapy for chronic non-cancer pain. The trials...
BioCentury | Jan 28, 2013
Finance

Oleg's asymmetry

Longtime BVF Partners portfolio manager Oleg Nodelman is betting there's room for a new fund focused on what he calls "asymmetric opportunities." Last October, Nodelman left the hedge fund after about 11 years to launch...
BC Week In Review | Jan 7, 2013
Clinical News

Entereg alvimopan regulatory update

On Dec. 21, 2012, Cubist said it submitted an sNDA to FDA for Entereg alvimopan to accelerate GI recovery following any surgery that includes a bowel resection with primary anastomosis. The mu opioid receptor ( OPRM1...
BC Week In Review | Nov 5, 2012
Clinical News

CB-5945: Phase III started

Cubist began a double-blind, placebo-controlled, North American Phase III trial to evaluate 0.25 mg oral CB-5945 twice daily for 1 year in about 1,400 patients receiving opioid therapy for chronic non-cancer pain. The long-term safety...
BioCentury | Oct 22, 2012
Finance

Abbott's wild ride

Abbott Laboratories (NYSE:ABT) had a rollercoaster ride last week, gaining $4.3 billion in market cap on positive HCV data before losing more than $8.6 billion on details of its AbbVie pharmaceutical spinout and safety signals...
BC Extra | Sep 5, 2012
Company News

Kalidex debuts

Kalidex Pharmaceuticals Inc. (Menlo Park, Calif.) made its public debut on Tuesday and said it raised $45 million in a series A round in February 2011. Frazier Healthcare Ventures; Domain Associates; Canaan Partners; New Leaf...
BioCentury | Jul 23, 2012
Finance

In like a lion . . .

Human Genome Sciences Inc. (NASDAQ:HGSI) roared into biotech in the early 1990s with its genomics database. But it's going out like a lamb after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to acquire the biotech last week...
Items per page:
1 - 10 of 432